Bromodomain-containing protein 4 (BRD4) mRNA 3' untranslated region (BRD4 mRNA 3' UTR)

The Bromodomain-containing protein 4 (BRD4) mRNA 3' untranslated region (3' UTR) is a critical regulatory segment of the transcript encoding the BRD4 protein, a key epigenetic reader and transcriptional co-activator (UniProt: O60885). BRD4 is well-characterized for its role in promoting the expression of oncogenes, most notably MYC, by binding to acetylated histones at enhancers and promoters (PubMed: 21840504). The 3' UTR of BRD4 serves as a hub for post-transcriptional control, containing multiple binding sites for microRNAs such as miR-204, miR-124, and miR-608, which negatively regulate BRD4 levels (PubMed: 27121130, PubMed: 28423609). In many cancers, the loss of these regulatory microRNAs leads to the pathological overexpression of BRD4, driving tumor progression and chemoresistance. Therapeutic strategies targeting this region include the development of microRNA mimics and antisense oligonucleotides (ASOs) designed to induce mRNA degradation or block translation (PubMed: 30217980). By reducing the abundance of the BRD4 transcript, these approaches aim to achieve more comprehensive inhibition of BRD4 signaling than traditional small-molecule bromodomain inhibitors. However, clinical application faces challenges such as the risk of systemic toxicity—including thrombocytopenia and gastrointestinal distress—and the need for efficient, targeted delivery of RNA-based therapeutics.

Other names

BRD4 3'-UTRBRD4 3' untranslated regionBromodomain-containing protein 4 transcript 3' untranslated region

Targeting of the 3' UTR by microRNA mimics or antisense oligonucleotides leads to the recruitment of the RNA-induced silencing complex (RISC) or RNase H, resulting in mRNA degradation or translational repression of the BRD4 transcript.